Preclinical Studies of T-Cell-Mediated Immune Responses Against Autologous Tumor Cells in Patients with Acute Leukemia

  • M. Notter
  • W.-D. Ludwig
  • E. Thiel
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 131)


Risk-adapted therapy in patients with acute leukemia has significantly improved prognosis. As a result of relapsing disease and increasing resistance to chemotherapy, however, long-term survival in nontransplanted patients does not exceed 30% (Büchner et al. 1985). Clearly, new therapeutic approaches are needed.


Acute Myeloid Leukemia Acute Leukemia Acute Myeloid Leukemia Patient Autologous Tumor Cell Specific Lysis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Büchner T, Urbanitz D, Hiddemann W, Rühl H, Ludwig WD, Fischer J, Aul HC, Vaupel HA, Kuse R, Zeile G, Nowrousian MR, König HJ, Walter M, Wendt FC, Sodomann H, Hossfeld DK, von Paleske A, Löffler H, Gassmann W, Hellriegel KP, Fülle HH, Lunschken C, Emmerich B, Pralle H, Pees HW, Pfreundschuh M, Bartels H, Koeppen KM, Schwerdtfeger R, Donhuijsen-Ant R, Mainzer K, Bonfert B, Köppler H, Zurborn KH, Ranft K, Thiel E, Heinecke A (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia ( AML ). J Clin Oncol 3: 9–17Google Scholar
  2. Foa R, Caretto P, Fierro MT, Bonferroni M, Cardona S, Guarinio A, Lista P, Pegoraro L, Mandelli F, Forni G, Gavosto F (1990) Interleukin 2 does not promote the in vitro and in vivo proliferation and growth of human acute leukemia cells of myeloid and lymphoid origin. Br J Haematol 75: 34–40PubMedCrossRefGoogle Scholar
  3. Foa R, Guarini A, Tos AG, Cardona S, Fierro MT, Meloni G, Tosti S, Mandelli F, Gavosto F (1991a) Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: evidence of in vivo lymphokine activated killer cell generation. Cancer Res 51: 964–968PubMedGoogle Scholar
  4. Foa R, Meloni G, Tosti S, Novarino A, Fenu S, Gavosto F, Mandelli F (1991b) Treatment of acute leukaemia patients with recombinant interleukin 2: a pilot study. Br J Haematol 77: 491 - 496PubMedCrossRefGoogle Scholar
  5. Gottlieb DJ, Prentice HG, Heslop HE, Bello-Fernandez C, Bianchi AC, Galazka AR, Brenner MK (1989) Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose radiochemotherapy for hematological malignancy. Blood 74: 2335 - 2342PubMedGoogle Scholar
  6. Gregory CD, Murray RJ, Edwards CF, Rickinson AB (1988) Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt’s lymphoma underlies tumor cell escape from virus-specific T cell surveillance. J Exp Med 167: 1811 - 1824PubMedCrossRefGoogle Scholar
  7. Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, Seipp CAY, Custer MC, Rosenberg SA (1985) In vivo administration of purified human Interleukin-2. J Immunol 4: 2865 - 2875Google Scholar
  8. Lotzova E, Savary CA, Herberman RB, McCredie KB, Keating MJ, Freireich EJ (1987) Augmentation of antileukemia lytic activity by OKT3 monoclonal antibody: Synergism of OKT3 and Interleukin-2. Nat Immun Cell Growth Regul 6: 219 - 223PubMedGoogle Scholar
  9. MacDonald D, Jiang YZ, Swirsky D, Vulliamy T, Morilla R, Bungey J, Barrett A J (1991) Acute myeloid leukemia relapsing following interleukin-2 treatment expresses the alpha chain of the interleukin-2 receptor. Br J Haematol 77: 43 - 49PubMedCrossRefGoogle Scholar
  10. Mukherji B, Guha A, Loomis R, Ergin MT (1987) Cell-mediated amplification and downregulation of cytotoxic immune response against autologous human cancer. J Immunol 138: 1987 - 1991PubMedGoogle Scholar
  11. Notter M, Schirrmacher V (1990) Tumor-specific T-cell clones recognize different protein determinants of autologous human malignant melanoma cells. Int J Cancer 45: 834 - 841PubMedCrossRefGoogle Scholar
  12. Oshimi K, Oshimi Y, Akutsu M, Takei Y, Saito H, Okada M, Mizogouchi H (1986) Cytotoxicity of Interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood 68: 938 - 948PubMedGoogle Scholar
  13. Rosolen A, Nakanishi M, Poplack DG, Cole D, Quinones R, Reaman G, Cotelingam JD, Trepel JB, Sausville E, Marti GE, Jaffe E, Neckers LM, Colamonici OR (1989) Expression of interleukin-2 receptor beta subunit in haematopoietic malignancies. Blood 73: 1968 - 1972PubMedGoogle Scholar
  14. Takeuchi T, Rudd CE, Schlossmann SF, Morimoto C (1987) Induction of suppression following autologous mixed lymphocyte reaction; role of a novel 2H4 antigen. Eur J Immunol 17: 97 - 103PubMedCrossRefGoogle Scholar
  15. Vieira P, De Waal-Malefyt R, Dang MN, Johnson KE, Kastelen R, Fiorentino DF, DeVries JE, Roncarolo MG, Mosmann TR, Moore KW (1991) Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: Homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci USA 88: 1172-1176PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1993

Authors and Affiliations

  • M. Notter
    • 1
  • W.-D. Ludwig
    • 1
  • E. Thiel
    • 1
  1. 1.Department of Hematology and OncologyFree University of BerlinBerlin 45Fed. Rep. of Germany

Personalised recommendations